Ernexa Therapeutics Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
1.17M
on 2026-06-30, from 14K on 2024-03-31 10-Q ↗
Earlier counts are adjusted for the 1-for-15 and 1-for-25 reverse splits; each bar's tip shows the count as filed.
a raise that quarter, at its price
Newest
$50.0M
S-3 of 2026-03-16. Sales under the at-the-market programme filed with it are not stated apart. S-3 ↗
$9.2M
Brookline Capital Markets, agreement of 2026-03-13. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗
Cash
2.3 quarters
$5.0M on 2026-06-30 ÷ $2.2M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-02-06 | Public offering incl. 2.00M pre-funded | 21,000,000 | $0.50 | $10.5M | 424B5 ↗ |
| 2025-03-31 | Private placement incl. 11.05M pre-funded | 69,311,654 | $0.1046 | not stated | 8-K ↗ |
Also on file: $1.5M promissory note, 2025-03-11 8-K ↗ · $750K promissory note, 2025-03-20 8-K ↗ · a 1-for-10 reverse split, 2025-06-02 8-K ↗ · a 1-for-15 reverse split, 2025-06-12 8-K ↗ · a 1-for-25 reverse split, 2026-05-04 8-K ↗